

DRIVE RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

23 September 2015



Don't forget: DRIVE-AB is on [Twitter!](#)

Don't miss a beat - follow us at [@DRIVE_AB](#).

We've made it easier for you to get involved! Just go to our website and click "Stakeholder Engagement" to find out all you need to know about getting involved with the project!

Or, fill out our [Expression of Interest Form](#) for stakeholders to let us know exactly how you or your organization would like to engage with the project. Please share this with other interested stakeholders as well!

What's New?

Work Package 1A administers survey and hosts stakeholder meeting

Work Package 1A, which aims to find a consensus definition for "responsible antibiotic use", has completed the first online survey of the RAND-modified Delphi method to achieve expert consensus on potentially relevant metrics and indicators for "responsible use". The survey will be followed by a [face-to-face consensus meeting](#) in Amsterdam on 30 September with stakeholders from a variety of fields, ranging from representatives of the medical community to pharmaceutical R&D and payers or policymakers.

To find out more or to express your interest in providing valuable input to these activities, please visit their [stakeholder engagement page](#).

Annual General Assembly to be held in Sweden

The [Annual DRIVE-AB General Assembly](#) is scheduled to take place in Uppsala, Sweden, on the 15th and 16th of October, 2015. The meeting will bring together DRIVE-AB partners and participants from all over the world to discuss the progress of the project over its first year of operation and to decide upon next steps. To read more about the event, please [click here](#).

HTA stakeholder meeting

WP2 and WP3B are organising a **meeting with health technology assessment (HTA) stakeholders** in London on November 6 to gain a better understanding of how the value for society of antibiotics can be reflected and utilized in HTA and/or reimbursement decisions.

DRIVE-AB Supports World Health Organization Survey on Antimicrobial Resistance

The WHO invites professionals working with AMR to participate in a short survey about the World Health Organization's activities for prevention and containment of antimicrobial resistance. The anonymous survey will be used to support the WHO in implementing its Global Action Plan. For more information, [click here](#).

Please [click here](#) to go directly to the survey.

What have we been up to?

DRIVE-AB goes to Capitol Hill, USA

An Antimicrobial Innovation Alliance meeting on **Stimulating the antimicrobial pipeline: A global perspective** was held on 18 June 2015 at the US Capitol Visitor Center on Capitol Hill in Washington DC, USA. The meeting was also supported by the Review on Antimicrobial Resistance and DRIVE-AB.

DRIVE-AB WP2 participant Christine Årdal gave a presentation at this meeting on **"Creating, Testing and Validating New Economic Models for Antibiotic R&D"**.

Please see the [DRIVE-AB website](#) for full details.



DRIVE-AB contributes to Uppsala Health Summit

The **Uppsala Health Summit** titled 'A World Without Antibiotics', invited experts, delegates of civil society, and industry leaders from around the world to meet 2-3 of June 2015 in Uppsala, Sweden, to discuss consequences of actions and of non-actions for people, animals and the planet, and to propose possible solutions to the global threat of antibiotic resistance.



DRIVE-AB had a number of representatives attending the Uppsala Health Summit and was closely involved in the preparation and management of the event.

To read more about the event, DRIVE-AB involvement, and to read the pre-conference report, please visit the [DRIVE-AB website](#).

Project updates by work package

Work Package 1

WP1A: Responsible use of antibiotics, new and old

The team has completed an extensive literature review on the definition of “responsible use” of antibiotics. They are in the process of obtaining feedback from experts through the use of surveys: stakeholders are being invited to provide feedback on the terminology, metrics and common themes identified in the systematic review. This survey is the first step in a Delphi method to achieve expert consensus on these metrics.

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see [WP1A's stakeholder engagement page](#).

WP1B: Setting, communicating and revising public health priorities

WP1B has produced the first mathematical model which examines the spread of multidrug resistant organisms within hospitals. This model is now being tested while work on a model of between hospital and regional spread is ongoing. The team is also in the process of completing a literature review to determine the clinical impact of antimicrobial resistance.

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see [WP1B's stakeholder engagement page](#).

WP1C: Antibiotic Evaluation

The team's first paper, “Potential burden of antibiotic resistance on surgeries and cancer chemotherapy antibiotic prophylaxis in the United States” is complete and will be published in the near future. Work on the other papers is ongoing and a list of stakeholders for consultation is being drafted.

For more detailed information on the group's progress and to find out how you can get involved, please see [WP1C's stakeholder engagement page](#).

Work Package 2

WP2: Creation and testing of new economic models

The team, along with the UK Antimicrobial Resistance Review and the Antimicrobial Innovation Alliance, hosted a [meeting at Capitol Hill in Washington DC, USA](#) to discuss global perspectives on how to stimulate development of the antimicrobial pipeline.

For more detailed information on the group's progress and to find out how you can get involved, please see [WP2's stakeholder engagement page](#).

Work Package 3

WP3A: Project management and governance

WP3A has been busy planning and organising the DRIVE-AB General Assembly meeting to be held in Uppsala, Sweden. The team will also be generating the annual progress report for IMI during the upcoming months.

For more detailed information on the group's progress, please see the [DRIVE-AB website](#).

WP3B: Stakeholder platform and external communication

WP3B is currently involved in the planning of various upcoming meetings and events, such as the the 2015 HTA stakeholder meeting in London. They have also developed a two-page [overview of](#)

the **DRIVE-AB project**, which is available in postcard form for easy dissemination, as well as a new **'Stakeholder Engagement' tab** on the website to facilitate stakeholder engagement.

For more detailed information on the group's progress, please see the **DRIVE-AB website**.

Other news



DRIVE-AB RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

www.drive-ab.eu

Driving reinvestment in R&D for antibiotics and advocating their responsible use

DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and is composed of 16 public and 7 private partners from 12 countries.

What is the problem?

Antibiotic resistance is a global public health threat that is getting worse every year. It is estimated that antibacterial drug resistance costs the EU at least EUR 1.5 billion and 25 000 lives each year. The development of new drugs to treat resistant infections is falling behind; new economic models that offer incentives for the discovery and development of new antibiotics and reconcile these with responsible antibiotic use and access are long overdue.

What we plan to do

- Define standards and metrics for **responsible antibiotic use**
- Estimate the current and future **impact of antibiotic resistance** on societies in order to determine future public health needs
- Quantify the **value of new antibiotics**
- Create, test and validate new **economic models to incentivise the discovery and development of new antibiotics**
- **Recommend to governments and policy-makers** new economic models that stimulate innovation, responsible use and global access of novel antibiotics to meet public health needs

imi innovative medicines initiative

EU

ND/BB

efpia

Work Package 3B has developed a two-sided information card offering a full, summarized **overview of the DRIVE-AB project**. These information cards are available for download on the **DRIVE-AB website**, along with other resources.

Please share these information cards with any colleagues or friends that may be interested in the project - the more stakeholders we have, the more robust and relevant our outputs will be!

Should you wish to receive more detailed information, nominate another stakeholder or update us on your activities as relevant to the project, please contact **Victoria Wells, DRIVE-AB Communications Officer.**

[Edit your subscription](#) | [Unsubscribe](#)